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ABSTRACT
The pharmacokinetics of cyclophosphamide (CY) and its metabolites hydroxycyclophosphamide and carboxy-
ethylphosphoramide mustard were determined in 75 patients receiving targeted oral busulfan followed by i.v.
CY (TBU/CY) and in 147 patients receiving i.v. CY followed by total body irradiation (CY/TBI) in preparation
for hematopoietic cell transplantation (HCT). In the TBU/CY patients only, the association of the pharma-
cokinetic data with liver toxicity, relapse, and survival was evaluated. CY was infused at 60 mg/kg/day over 1
or 2 hours on 2 consecutive days; the majority of patients had BU levels targeted to a steady state plasma
concentration (Css) of 800-900 ng/mL. Systemic exposure (i.e., area under the concentration-time curve
[AUC]) of CY, hydroxycyclophosphamide, and carboxyethylphosphoramide mustard was measured. Liver
toxicity was assessed as the development of hepatic sinusoidal obstruction syndrome (SOS). CY metabolism
was highly variable and age dependent. TBU/CY-treated patients had lower AUCCY (P < .0001), higher
AUCHCY (P < .0001), and higher AUCCEPM (P  .15) than CY/TBI-conditioned patients. Among patients
receiving TBU/CY, 17 (23%) developed SOS, and there were no statistically significant associations between
the AUC of CY or its metabolites and SOS, nonrelapse mortality, relapse, or survival (all P>.15). In conclusion,
CY exhibits conditioning-regimen dependent pharmacokinetics and pharmacodynamics, suggesting that low-
ering CY doses is unlikely to improve outcomes to TBU/CY. Alternative strategies, such as administering i.v.
busulfan or CY before BU, should be explored.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
A myeloablative conditioning regimen combining
usulfan and cyclophosphamide (BU/CY) is frequently
sed to prepare patients for hematopoietic cell trans-
lantation (HCT) [1]. Several reports suggested that
inusoidal liver toxicity was associated with elevated BU
xposure in patients receiving high dose BU (1 mg/kg/
ose orally every 6 hours for 16 doses) followed by CY
2-4]. Speciﬁcally, liver toxicity was observed with a
U area under the plasma-concentration time curve tAUC) 1250 [2] or 1500 M · h [3,4]. These corre-
pond to a BU steady-state concentration (Css) of 925
r 1025 ng/mL, respectively, when BU is dosed every
hours for 16 doses. This association was observed
redominantly in adult populations receiving HCT
or various diseases. On the other hand, studies in
atients with chronic myelogenous leukemia (CML)
n the chronic phase who received BU/CY showed
hat BU Css 900 ng/mL did not correlate with liver
oxicity, but was inversely related to the risk of leuke-
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J. S. McCune et al.854ic relapse [5,6]. In vitro studies with murine hepa-
ocytes revealed that BU depletes hepatic glutathione
nd at high concentrations induces oxidative stress [7].
any HCT teams adjust BU doses to a target Css to
inimize the risks of liver toxicity, rejection, and
elapse [8]. In combination with CY, BU administered
ntravenously (i.v.) is associated with lower rates of
iver toxicity than when given orally when the drug is
osed by body weight (i.e., not targeted) [9,10]. Liver
oxicity occurs in 5% [9] to 18% [10] of patients
eceiving BU/CY with i.v. BU dosed by body weight
0.8 mg/kg i.v. every 6 hours for 16 doses). Thus,
egimen-related toxicity has remained a problem in
atients conditioned with targeted oral BU/CY (TBU/
Y) [6,11,12] and with weight-based dosing of i.v. BU
9,10,13].
As targeting BU doses minimized interpatient
ariability in exposure, we hypothesized that regimen-
elated toxicity in TBU/CY conditioned patients was
elated to variability in CY metabolism. In vitro stud-
es of isolated hepatocytes and sinusoidal endothelial
ells incubated with CY showed that sinusoidal endo-
helial cells were highly sensitive to CY metabolites
enerated by hepatocytes, consistent with the clinical
icture of sinusoidal liver toxicity [14]. The AUC of
.v. CY is more variable than that of oral or i.v. BU
15-17]. Higher exposure to the CY metabolite
arboxyethylphosphoramide mustard (CEPM) was
trongly correlated with liver toxicity and mortality in
47 patients conditioned with a regimen of CY fol-
owed by total body irradiation (TBI), that is, 23
atients (16%) developed moderate or severe sinusoi-
al obstruction syndrome (SOS) [15]. Exposure to
EPM correlated statistically signiﬁcantly with the
evelopment of SOS, nonrelapse mortality (NRM),
nd survival, after adjusting for age and irradiation
ose. There was no signiﬁcant correlation with en-
raftment and tumor relapse. These in vitro and in
ivo data suggest that metabolites of CY are toxic to
epatic sinusoids, thereby causing SOS. Accordingly,
e evaluated the pharmacodynamic relationship be-
ween the exposure to CY and 2 of its metabolites,
ydroxycyclophosphamide (HCY) and CEPM, with
linical outcome in patients conditioned with TBU/
Y. As CY pharmacokinetics have been found to be
ependent upon the type of conditioning regimen [18],
e also compared the pharmacokinetics of CY, HCY,
nd CEPM between patients who received TBU/CY
i.e., CY following BU) and patients (previously re-
orted) who received CY/TBI (i.e., CY ﬁrst) [15].
ATERIALS AND METHODS
atient Selection
Patients 18 to 65 years of age were eligible for
tudy participation if they had a diagnosis of myelo- oysplastic syndrome, myeloﬁbrosis, or another hema-
ologic malignancy for which a transplant condition-
ng regimen of TBU/CY was appropriate. Related
atient/donor pairs were HLA identical by high res-
lution DNA typing. Unrelated donors were selected
n the basis of high-resolution HLA typing as de-
cribed [19,20]. Written consent was obtained using
orms approved by the institutional review board of
he Fred Hutchinson Cancer Research Center.
Patient, disease, and transplant characteristics of
he cohort receiving TBU/CY conditioning are sum-
arized in Table 1. Seventy-ﬁve patients, 20-66 years
f age, were conditioned with TBU/CY (49 with my-
lodysplastic syndrome [MDS], 20 with acute myelog-
nous leukemia [AML], and 6 with CML). Hemato-
oietic cell donors were family members for 42
atients and unrelated individuals for 33 patients.
The patient, disease, and transplant characteristics
nd the pharmacodynamics of CY and metabolites of
he cohort receiving CY/TBI conditioning have been
reviously published [15].
onditioning Regimen
The conditioning regimen of TBU/CY consisted
f oral BU, 1 mg/kg administered every 6 hours (total
f 16 doses, adjusted for plasma target levels as de-
cribed below) followed by i.v. CY, 60 mg/kg admin-
stered every 24 hours for 2 doses. In a subset of
atients (N  21), thymoglobulin was given, starting
able 1. Patient, Disease, and Transplant Characteristics of Patients
eceiving TBU/CY
umber of patients 75
gea (years) 47  11
(20-66)
en:women 41:34
iagnosisb
Myelodysplastic syndrome
Refractory anemia 30 (40%)
Refractory anemia with excess blasts 10 (13%)
Myelofibrosis 4 (6%)
Chronic myelomonocytic leukemia 3 (4%)
Refractory anemia with ring sideroblasts 2 (3%)
Acute myelogenous leukemia 20 (26%)
Chronic myelogenous leukemia 6 (8%)
onorsc
Related
HLA-identical sibling 38 (51%)
HLA-nonidentical family memberc 4 (5%)
Unrelated 33 (44%)
ntifungal drugs administered with
cyclophosphamideb
Fluconazole 56 (75%)
Voriconazole vs. fluconazole 12 (16%)
Other 7 (9%)
Mean  standard deviation (range).
Data are reported as number (percentage) of participants.
HLA nonidentical sibling in three and parent in one patient.n the same day as CY and continued over 3 days for
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CY Kinetics in the BU/CY Regimen 855umulative doses of 4.5 or 6 mg/kg [12]. Donor he-
atopoietic cells were infused 48 hours after the last
ose of CY (day 0).
BU doses were adjusted to a target Css as previ-
usly described [2]; the target Css was 800-900 ng/mL
or 69 patients, 900-1000 ng/mL for 1 patient (with
ML) and900 ng/mL for 5 patients (all with CML).
lood sampling for BU pharmacokinetics occurred
fter doses 1, 5, and 9 (at 0, 30, 60, 90, 120, 240, 300,
nd 360 minutes after dose 1; and at 0, 60, 120, 240,
nd 360 minutes after doses 5 and 9). Rapid quantita-
ion of BU plasma concentrations was achieved by gas
hromatography-mass spectrometry, with a concen-
ration range of 25 to 4500 ng/mL and interday co-
fﬁcient of variability of 8%. Determination of the
ss and clearance of oral BU was calculated by non-
ompartmental methods using WinNonlin (Phar-
ight, Mountain View, CA). The estimate of BU clear-
nce (dose/AUC) was used to calculate the dose
equired to achieve the desired Css (clearance target
ss  time between doses). BU doses were adjusted
ithin 3 hours of the last pharmacokinetic sample (i.e.,
he Css estimated from dose 1 was utilized for dose 3).
verage BU Css was calculated as the mean dose/
mean clearance)(dosing interval). The mean clear-
nce was calculated as the mean of these values mea-
ured after doses 1, 5, and 9.
Seizure prophylaxis consisted of phenytoin given
s a loading dose of 10-15 mg/kg at least 6 hours
efore BU administration, followed by maintenance
oses of 300 mg orally once daily until 24 hours after
he ﬁnal BU dose.
CY was infused through a central venous access
atheter over 1 or 2 hours at doses of 60 mg/kg
djusted ideal body weight per day on 2 consecutive
ays. The infusion duration followed Fred Hutchin-
on Cancer Research Center Standard Practice
uidelines. Speciﬁcally, total CY doses of 5000 mg
ere infused over 1 hour, and CY doses equal to or
5000 mg were infused over 2 hours. The ﬁrst CY
ose was administered 12-15 hours after the last oral
U dose. CY doses were ﬁxed; no adjustments were
ade. During the days of CY infusion, patients re-
eived MESNA (2-mercaptoethane sulfonate) pro-
hylaxis for uroepithelial protection at milligram
oses equal to those of CY.
The use of all antifungal agents administered con-
omitantly with the conditioning regimen was re-
orded because some prophylactic antifungal agents
e.g., ﬂuconazole and itraconazole) inhibit cyto-
hrome P450 (CYP) activity and may inﬂuence CY
harmacokinetics [21]. Antifungal prophylaxis given
oncomitantly with CY administration consisted of
uconazole in 56 patients; 12 patients were enrolled in
blinded, randomized trial comparing ﬂuconazole to
oriconazole, 5 received miscellaneous antifungal pro-
hylaxis (2 received liposomal amphotericin, 1 caspo- (ungin, 1 itraconazole, and 1 voriconazole), and 2
atients received no antifungals (Table 1).
easurement of Cyclophosphamide (CY)
nd Its Metabolites
Blood samples were drawn from a central venous
ccess catheter at end, 4, 8, 20 and 24 hour post end of
ach of the 2 CY infusions. A 5-mL sample of blood
as collected at each of these time points and divided
etween 1 tube containing EDTA for CY and CEPM
uantitation, and a second tube containing phenylhy-
razine HCl to stabilize HCY [22]. All samples were
tored at the bedside at 4°C until sample transport
ithin 12 hours to the Pharmacokinetics Laboratory
or quantitation of the plasma concentrations of CY,
CY, and CEPM by liquid chromatography and mass
pectroscopy methods [22]. The exposure to CY and
ts metabolites was calculated by determining the
UCCY, AUCHCY, and AUCCEPM for time 0 to 48
ours, using noncompartmental analysis.
valuation of Clinical Outcomes
Liver toxicity was deﬁned by the presence of SOS,
nd its severity was recorded [15,23]. Patients without
vidence of liver disease were categorized as not hav-
ng SOS, and patients in whom liver disease developed
efore day 20 after HCT that did not meet the criteria
or SOS (but might result from, e.g., to acute graft-
ersus-host disease or cholangitis lenta) were catego-
ized as having liver disease of unknown etiology, as
reviously described [23]. Liver toxicity was assessed
ithout knowledge of the pharmacokinetic data.
eath that occurred following progression or recur-
ence of the underlying hematologic disease was cat-
gorized as resulting from disease recurrence (re-
apse), regardless of the proximate cause; death in the
bsence of relapse was categorized as NRM. The time
o last follow-up for overall survival is a median of
17 days (range: 300-1916) for those who received
BU/CY.
tatistical Methods
Pharmacokinetic data in patients who received
BU/CY and CY/TBI were compared using the
-sample t-test (for unadjusted comparisons) and lin-
ar regression (for age-adjusted comparisons). Pa-
ients were categorized as receiving ﬂuconazole versus
hose who did not, to allow for comparison of phar-
acokinetics between the 2 conditioning regimens.
or patients conditioned with TBU/CY, logistic re-
ression was used to assess the relationship between
he exposure (i.e., AUC) to CY and its metabolites and
he occurrence of SOS. Associations between the ex-
osure to CY and its metabolites and the time-to-
vent outcomes relapse, overall mortality, and NRM
occurring by day 200 and to time of last follow-up)
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J. S. McCune et al.856ere assessed using Cox regression. Regression mod-
ls were adjusted for type of donor (HLA identical
ibling vs. others) and patient age at the time of HCT.
UC was modeled as a continuous linear variable in
he regression models, and nonlinear terms were ad-
itionally examined to account for the possibility of
uch associations. Two-sided P-values from regression
odels were obtained from the Wald test, and no
djustments were made for multiple comparisons.
ESULTS
usulfan Pharmacokinetics
After a 1 mg/kg dose of oral busulfan, the mean
SD) plasma level was 976  171 ng/mL with a
.2-fold range (592-1312 ng/mL). The target Css
ange was achieved in 93% of patients. Speciﬁcally,
mong 69 patients with a target Css of 800-900 ng/
L, 64 achieved this target with a mean oral BU total
ose of 14.6 (range: 9.8-22.3) mg/kg. The BU Css was
able 2. Relation of Busulfan Dose Adjustments to Achieve Target Css
nd the Development of SOS
SOS
No
(N  50)
Yes
(N  17)
ose 5 0.95  0.16 0.89  0.13
ose 1 (0.69-1.38) (0.67-1.23)
ose 9 0.99  0.09 0.96  0.06
ose 5 (0.8-1.24) (0.8-1.03)
usulfan dose 1 was 1 mg/kg for all patients; doses 5 and 9 were
adjusted to achieve target Css.
ss indicates steady state plasma concentration; SOS, sinusoidal
obstruction syndrome.
able 3. Comparison of Pharmacokineticsa of CY, HCY, and CEPM by
CY/TBI T
Y
Peak [CY]a, day 1 364  52 31
Peak [CY], day 2 358  54 28
AUCCY 6134  1249 256
CY
Peak [HCY], day 1 7  4 3
Peak [HCY], day 2 14  7 3
AUCHCY 152  62 29
EPM
Peak [CEPM], day 1 11  5 2
Peak [CEPM], day 2 21  9 3
AUCCEPM 416  186 52
UC indicates area under the curve; CEPM, carboxyethylphosp
irridiation; BU, busulfan; CY, cyclophosphamide.
Peak concentrations (M) are the highest concentration quantitat
Two-sample t-test unadjusted for age.
CY/TBI-TBU/CY, P-values adjusted for patient age at transplant.11-963 ng/mL, that is, outside of the target range, in
patients. All 5 CML patients with a target BU Css
900 ng/mL reached that target Css (range: 923-959
g/mL), and the 1 patient whose target was 900-1000
g/mL had a BU Css of 946 ng/mL. The ﬂuctuations
n BU dosing to achieve target Css are described in
able 2, based on whether the patient developed SOS.
omparison of CY Pharmacokinetics in Patients
ho Received CY First in Order (i.e., CY
ollowed by TBI) versus Second in Order,
ollowing TBU
Peak plasma concentrations and AUCs of CY,
CY, and CEPM are summarized in Table 3. There
as considerable interpatient variability in exposure
expressed as the AUC from 0 to 48 hours) to CY
8.7), HCY (5.4), and CEPM (8.1). Patients who
eceived TBU/CY were, on average, older than those
ho received CY/TBI (46.6 years vs. 35.3 years, P 
0001), and subsequent analyses comparing the AUCs
f CY, HCY, and CEPM were adjusted for age using
inear regression models. Patients receiving TBU/CY
ad a statistically signiﬁcantly lower AUCCY and
igher AUCHCY in comparison to those receiving CY
ithout preceding exposure to BU and phenytoin (i.e.,
hose conditioned with CY/TBI [15]). These differ-
nces were essentially unchanged after adjusting for
ge (Table 3). Patients who received TBU/CY also
ad higher AUCCEPM, but the difference was not
tatistically signiﬁcant after adjusting for age (Table 3).
he unadjusted AUCs are depicted in Figure 1.
The difference in AUCs between the 2 condition-
ng regimens did not appear to be dependent on con-
omitant ﬂuconazole use. There was a suggestion that
he difference for AUCCY between CY/TBI and
BU/CY was dependent on concomitant ﬂuconazole
P  .08). Patients conditioned with TBU/CY had a
tioning Regimen
P-Valueb
Age-Adjusted Difference,c
P-Value
1 <.0001 67, <.0001
4 <.0001 85, <.0001
90 <.0001 3887, <.0001
<.0001 29, <.0001
<.0001 23, <.0001
<.0001 134, <.0001
<.0001 15, <.0001
<.0001 6, <.04
4 <.0001 40, .15
ide mustard; HCY, hydroxycyclophosphamide; TBI, total body
that day; AUC (M · h) is from time 0 to 48 hours.Condi
BU/CY
2  17
3  12
3  11
5  18
6  13
0  98
7  12
2  29
2  19
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CY Kinetics in the BU/CY Regimen 857ower AUCCY than those who received CY/TBI, re-
ardless of ﬂuconazole use. In patients receiving con-
omitant ﬂuconazole, the mean AUCCY for
TBU/CY
as 2894 1173 M · h and for CY/TBI was 6236
221 M · h (P  .0001). In those not receiving ﬂu-
onazole concomitant with CY, the mean AUCCY for
BU/CY was 1588 517 M · h and for CY/TBI was
638  1288 Mh (P  .0001). A test of interaction
etween conditioning regimen and concomitant ﬂu-
onazole use yielded a P  .94 for AUCHCY and P 
61 for AUCCEPM, indicating that concomitant ﬂu-
onazole use did not have a signiﬁcant impact on the
ifference in AUCHCY and AUCCEPM between the 2
onditioning regimens.
The association between the AUCCY and its me-
abolites was also examined in an attempt to conﬁrm
ur ﬁndings of conditioning regimen-dependent
harmacokinetics in a previously reported limited
umber of patients who had received BU/CY (N  7)
r CY/TBI (N  7) [18]. In patients receiving CY/
BI, there was little correlation between AUCCY and
UCHCY (R
2  .034, top panel of Figure 2) or
UCCEPM (R
2  .005, bottom panel of Figure 2).
imilarly, in patients receiving TBU/CY, there was
ittle correlation between AUCCY and AUCHCY (R
2
0004, top panel of Figure 2) or AUCCEPM (R
2  .02,
ottom panel of Figure 2). The associations between
verage BU Css and the AUC of CY and its metabo-
ites were weak (R2  .08 for AUCCY, R
2  .02 for
UCHCY, and R
2  .0002 for AUCCEPM).
In summary, the administration of i.v. CY after
U/phenytoin led to a marked reduction in the
UCCY and an increased AUC of both metabolites in
omparison to CY administered ﬁrst (i.e., CY fol-
owed by TBI). The AUC of the metabolites was not
igure 1. Comparison of CY, HCY, and CEPM exposure by
onditioning regimen. The AUC0-48hr in patients receiving CY/
BI (gray shading) and TBU/CY (no shading). Box designates
5th, 50th, and 75th percentile. Whiskers designate the extremes
ith one AUCCEPM of 1881 M · h in the CY/TBI (gray shading)
eing excluded for easier presentation.nﬂuenced by concomitant administration of ﬂucon- Azole with CY and also could not be predicted by the
xposure to CY or BU.
harmacodynamic Relationship between
linical Outcomes and CY and Metabolite AUCs
fter TBU/CY
The AUCs for CY, HCY, and CEPM were mod-
led as continuous linear variables with respect to each
ndpoint, as higher order terms for AUC did not
tatistically signiﬁcantly improve the models contain-
ng only a linear term. Moderate to severe SOS was
ot statistically signiﬁcantly related to AUCCY,
UCHCY, or AUCCEPM (Table 4). The relationships
etween AUCCY, AUCHCY, or AUCCEPM and re-
apse, NRM, or survival are summarized in Table 5.
RM at day 200 was related to AUCCY (p  .03), but
he association was no longer signiﬁcant at the time of
ast follow-up. Fifteen of the 75 TBU/CY conditioned
atients (20%) died from nonrelapse causes, 5 from
nfections (3 with aspergillosis, 1 with encephalitis/
entriculitis, 1 with disseminated cytomegalovirus dis-
ase), 4 from pulmonary complications (2 adult respiratory
istress syndrome; 1 pneumonia; 1 idiopathic pneu-
onia syndrome), 2 from multiorgan failure, 2 from
raft-versus-host disease (GVHD), 1 from SOS, and 1
ommitted suicide. Further, AUCCY, AUCHCY, or
UCCEPM were not correlated with relapse or overall
ortality.
ISCUSSION
The key ﬁndings of this study were the striking
harmacokinetic differences in CY and its metabolites
etween the myeloablative conditioning regimens
BU/CY and CY/TBI, and the apparent lack of a
harmacodynamic relationship between exposure to
Y and its metabolites with clinical outcomes follow-
ng the TBU/CY regimen. In the cohort of patients
eceiving TBU/CY, the AUCs of CY and HCY (but
ot CEPM) were profoundly affected by BU and the
oncomitantly administered phenytoin, compared to
Y given ﬁrst in order (Figure 1). In patients receiving
BU/CY, the CY metabolism showed large interpa-
ient variability when CY dose (mg/kg), phenytoin
ose (mg/kg), and BU Css (ng/mL) were held con-
tant between patients (Figure 1). In comparison to
Y/TBI patients in whom CY was administered ﬁrst,
BU/CY patients had a decreased AUCCY and in-
reased AUCHCY, whereas the difference was not sta-
istically signiﬁcant for AUCCEPM after adjusting for
atient age. Our ﬁnding of age-dependent pharmaco-
inetics of CY is consistent with previous reports and
as adjusted for within our statistical analysis [24-29].
luconazole use did not appear to have an impact on
he difference between conditioning groups for the
UCs of CY, HCY, and CEPM [21,30,31]. Our ﬁnd-
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J. S. McCune et al.858ngs of altered CY pharmacokinetics with preceding
U/phenytoin were also consistent with previous re-
orts, with the addition of data related to exposure to
EPM [18,32].
Busulfan without phenytoin has been shown to
nhibit CY metabolism [33]. The interaction between
igure 2. Relationship between AUC of CY and its metabolites in
anel, AUCCY (x-axis) versus AUCHCY (y-axis); bottom panel, AUhenytoin and CY is complex in that competitive inhibition or induction (or both) could occur. Phenyt-
in is a substrate for CYP2C9, CYP2C19, and
BCC2 [34,35]. Thus, phenytoin could competitively
nhibit the metabolism of CY to HCY by CYP2C9
nd CYP2C19 [36,37] and the elimination of gluta-
hionylcyclophosphamide by ABCC2 [38]. Phenytoin
ts receiving preparative regimens of TBU/CY and CY/TBI. Top
axis) versus AUCCEPM (y-axis).patiens also a well-recognized inducer of CYP2B6, 2C, and
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CY Kinetics in the BU/CY Regimen 859A, all of which catalyze HCY formation [34,39];
henytoin has not been reported to induce hepatic
BCC2 activity. In the data presented here, the in-
uctive effects of phenytoin were evidenced by the
ecreased AUCCY and increased AUCHCY. Pretreat-
ent with phenytoin increased AUCHCY by approxi-
ately 100%, which is consistent with other reports
18,40]. Patients conditioned with CY/TBI had dra-
atic changes in the pharmacokinetics of CY, HCY,
nd CEPM between dose 1 and 2 because of CY
utoinduction. Patients receiving TBU/CY showed
inimal differences between the metabolite AUCs of
ose 1 and dose 2, indicating that CY autoinduction
as not a major factor in patients who received an-
ther inducer (i.e., phenytoin), presumably because
he maximal metabolic rate was already obtained
41,42]. In agreement with our previous data, there
as only little correlation between the systemic expo-
ure to CY (i.e., AUCCY) and its metabolites HCY and
EPM (Figure 2) [18]. Similarly, BU Css was not
trongly associated with the AUCCY, AUCHCY, and
UCCEPM.
The lack of a statistically signiﬁcant relationship
etween systemic exposure to CY and its metabolites
nd clinical outcome contrasts with our report that
howed that AUCCEPM was strongly correlated with
able 4. Frequency of Sinusoidal Liver Toxicity among Patients
onditioned with TBU/CY
SOS
P-ValuebNo (N  50) Yes (N  17)
UCCY
a 2450  1213 2680  1046 .49
UCHCY 293  109 287  67 .82
UCCEPM 483  183 550  162 .18
UC indicates area under the curve; CEPM, carboxyethylphos-
phoramide mustard; HCY, hydroxycyclophosphamide; BU,
busulfan; CY, cyclophosphamide.
All AUCs expressed as AUC from time 0 to 48 hours in units of
M · h.
Two-sided p-values from regression models adjusted for age at
time of HCT and type of donor. With exclusion of eight (11%),
patients were classiﬁed as having liver disease of unknown eti-
ology.
able 5. Relationship between Exposure to CY and Its Metabolites and
Clinical Outcome Nb AUC
ay 200 Nonrelapse mortality 9 HR  0.36
onrelapse mortality 15 HR  0.76
elapse 16 HR  0.81
verall mortality 26 HR  0.85
UC indicates area under the curve; BU, busulfan; CY, cyclophosp
AUC modeled as continuous linear variable, with hazard ratios f
associated with increase in AUC of 100 M · h. HR for AU
1000 M · h. HR adjusted for age at time of HCT and type oNumber of events in cohort of 75 patients.iver toxicity and mortality in patients conditioned
ith CY/TBI [15]. TBI is toxic to hepatic sinusoids, as
emonstrated by the work of Geraci et al. [43] in a rat
odel and in our own clinical pharmacodynamic
tudy [15]. The lack of a pharmacodynamic relation-
hip with liver toxicity also contrasts with the obser-
ation that reducing the CY dose from 200 mg/kg to
20 mg/kg lowered liver toxicity in patients receiving
U/CY conditioning [44]. Liver toxicity was not ob-
erved after administration of single agent CY 150
g/kg [45] or 200 mg/kg [46]; however, multiple case
eports have been published of the liver toxicity in
atients receiving single-agent CY [47-49]. Single-
gent therapy with oral BU (1 or 1.25 mg/kg every 6
ours for 16 doses) led to bilirubin greater than 2
g/dL in all 6 patients; however, 1 patient had no
vidence of drug toxicity upon autopsy and another
ad chronic active hepatitis [50]. As a pharmacody-
amic relationship was not apparent, other risk factors
or SOS and NRM are likely contributing to the
oxicity of this TBU/CY preparative regimen.
The available data suggest that the concentration
ffect (i.e., the pharmacodynamic) relationship of CY
nd its metabolites is dependent upon the condition-
ng regimen [15,51-53]. This trend has been observed
peciﬁcally with BU in that BU exposure was related
o liver toxicity in BU/CY, but not BU/melphalan or
U/thiotepa regimens [2-4]. Also, the pharmacody-
amic relationship of BU and liver toxicity in adults
iffer based on disease, such that higher BU Css is
ssociated with a higher risk of liver toxicity in pa-
ients with diseases other than CML in the chronic
hase [2-4,13,54-58].
Nevertheless, the TBU/CY regimen used here re-
ulted in a 20% NRM rate at day 200 post-HCT,
hich raised the question as to whether regimen-related
oxicity from TBU/CY could be reduced bymodiﬁcation
f the regimen. In the BU/CY regimen, i.v. busulfan has
een reported to result in lower rates of SOS than the
ral BU, when both were given on the basis of body
eight and not dose adjusted to achieve target Css [9,10].
n a cohort of patients receiving BU without phenytoin
ollowed by CY, Hassan et al. [33] observed a higher
Outcomes among Patients Conditioned with TBU/CYa
Pharmacokinetic Parameters
AUCHCY AUCCEPM
3) HR  1.11 (P  .71) HR  1.01 (P  .97)
1) HR  0.82 (P  .45) HR  1.01 (P  .96)
3) HR  0.82 (P  .49) HR  0.88 (P  .46)
1) HR  0.76 (P  .24) HR  0.99 (P  .91)
e.
CCEPM and AUCHCY representing increase in hazard ratio (HR)
presents increase in hazard associated with increase in AUC of
.Clinical
CY
(P  .0
(P  .3
(P  .4
(P  .4
hamid
or AU
CCY re
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J. S. McCune et al.860UCCY, lower AUCHCY, and higher incidence of SOS
ith a 7-15 hour time interval between BU and CY
dministration in comparison to a 24-48 hour time in-
erval between the last BU dose and CY, suggesting that
prolonged time interval between administration of BU
nd CY may be beneﬁcial. Switching the administration
rder to CY followed by BU (i.e., CY/BU) may decrease
iver toxicity and, thus reduce NRM, although its impact
pon efﬁcacy has not been evaluated. Preclinical data in
ice suggest that a CY/BU conditioning regimen leads
o more rapid engraftment of donor cells and lower
lasma cytokine and serum hepatic enzyme levels than
bserved with BU/CY [59]. In addition, the incidence
f SOS was signiﬁcantly lower when BU was admin-
stered second, not ﬁrst, in children receiving myeloa-
lative conditioning regimens with 3 alkylating agents
60]. Another strategy to reduce regimen-related tox-
city may be to abandon CY in favor of ﬂudarabine,
hat is, to use a BU/ﬂudarabine regimen. The BU/
udarabine regimens studied thus far appear to have
ower rates of regimen-related toxicity than BU/CY
egimens, although randomized trials are needed to
ompare not only efﬁcacy, but also long-term toxicity
f these 2 conditioning regimens [61-63].
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